Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01303419 · ClinicalTrials.gov registry record · NA
Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer
A NA study, sponsored by GE Healthcare.
- Terminated
- Registry status
- NA
- Development phase
- 224
- Enrollment target
NCT01303419: Clinical Trial NA study, sponsored by GE Healthcare.
NCT01303419 is a NA study that was terminated before completion, run by GE Healthcare. The registered enrollment target is 224 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01303419, a NA study, was terminated before completion, sponsored by GE Healthcare.
- TERMINATED
- Registry status
- NA
- Development phase
- 224 participants
- Enrollment target
Study Summary
Enrolled women will undergo a bilateral Contrast-Enhanced Breast Magnetic Resonance Imaging (CE-BMRI) as per usual clinical practice within 30 days of breast cancer diagnosis. Up to 8 weeks after the CE-BMRI exam, subjects will undergo a Dual Energy Contrast Enhanced Digital Mammograph (DE-CEDM).
Primary Outcome
Subjects have completed both CE-BMRI and DE-CEDM scan types
Interventions
- DEVICE CE-BMRI
- DEVICE DE-CEDM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-06-30 |
| Phase | NA |
Why NCT01303419 stopped before completion
NCT01303419 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which CE-BMRI is the first listed.
NCT01303419 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01303419 about?
NCT01303419 is a clinical study titled "Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer". Enrolled women will undergo a bilateral Contrast-Enhanced Breast Magnetic Resonance Imaging (CE-BMRI) as per usual clinical practice within 30 days of breast cancer diagnosis. Up to 8 weeks after the CE-BMRI exam, subjects will undergo a Dual Energy Contrast Enhanced Digital Mammograph (DE-CEDM).
What is the current status of trial NCT01303419?
This trial is currently terminated. It is a NA study. The enrollment target is 224 participants. The study started on 2010-04. Estimated completion is 2012-06-30.
What interventions are being tested in trial NCT01303419?
The interventions under investigation include: CE-BMRI (DEVICE), DE-CEDM (DEVICE).
Who is sponsoring clinical trial NCT01303419?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01303419's enrollment target sits among peer trials
224 478th of 2000 higher than 1,520 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
- NCT04140344 · 224 participants · NA
The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions
- NCT04915183 · 224 participants · Phase 2
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- NCT05519878 · 224 participants · NA
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia